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Essentials 
• Mouse platelets have strikingly higher copy numbers of some proteins compared to 
human platelets 
• Functional implications of discrepancies are explored using a systems pharmacology 
model of GPVI 
• Interspecies differences in protein expression do not impact the regulation of GPVI 
signalling  
• Regulation of GPVI signalling is spatially regulated at the platelet membrane in 




Abstract (249 words) 
Background 
Accurate protein quantification is a vital prerequisite for generating meaningful predictions 
when using systems biology approaches, a method that is increasingly being used to unravel 
the complexities of sub cellular interactions and as part of the drug discovery process.   
Quantitative proteomics, flow cytometry and western blotting have been extensively used to 
define human platelet protein copy numbers, yet for mouse platelets, a model widely used 
for platelet research, evidence is largely limited to a single proteomic dataset in which the 
total amount of proteins were generally comparatively higher than those found in human 
platelets.   
Objectives 
To investigate the functional implications of discrepancies between levels of mouse and 
human proteins in the GPVI signalling pathway using a systems pharmacology model of 
GPVI 
Methods 
The protein copy number of mouse platelet receptors was determined using flow cytometry.  
The Virtual Platelet, a mathematical model of Glycoprotein VI (GPVI) signalling, was used to 
determine the consequences of protein copy number differences observed between human 
and mouse platelets.  
Results and conclusion 
Despite the small size of mouse platelets compared to human platelets they possessed a 
greater density of surface receptors alongside a higher concentration of intracellular 
signalling proteins.  Surprisingly the predicted temporal profile of Syk activity was similar in 
both species with predictions supported experimentally.  Super resolution microscopy 
demonstrates that the spatial distribution of Syk is similar between species, suggesting that 
the spatial distribution of receptors and signalling molecules, rather than their copy number, 




Platelets are small anucleate cells which play a vital role in vascular integrity and the 
prevention of excessive bleeding.  In addition to this key role in haemostasis inappropriate 
platelet regulation contributes to cardiovascular and inflammatory diseases.  These platelet 
mediated processes involve receptor-ligand interactions and the initiation of complex 
signalling cascades.  Indeed, current antiplatelet drugs target receptor-ligand interactions or 
signalling cascades to reduce cardiovascular events, but also have the side effect of an 
increased risk of bleeding.  There is therefore a pressing need for safer antiplatelet drugs, 
but the high cost of clinical trials has discouraged drug development.  Pharmaceutical 
companies are increasingly adopting quantitative systems pharmacology (QSP) approaches 
to determine mechanisms of action of new and existing drugs and to better utilise pre-clinical 
data to optimise clinical trial design(1, 2). QSP benefits greatly from published quantitative 
data such as receptor and signalling protein expression levels so that theoretical models can 
generate more accurate predictions.  
GPVI, a receptor for collagen, laminin and more recently recognised as a receptor for fibrin 
and fibrinogen, represents an attractive anti-thrombotic target in experimental models with 
expression limited to platelets and megakaryocytes(3-11).  Following ligand engagement a 
signalling cascade is initiated which culminates in platelet activation.  While the major 
components of this pathway are well known the underlying mechanism of activation has not 
yet been fully elucidated.  Antagonists of the platelet collagen receptor GPVI and Btk 
inhibitors (that inhibit signalling evoked by GPVI) are recognised as potential antiplatelet 
drugs(12-19), although copy numbers of receptors and signalling molecules involved in the 
GPVI signalling pathway vary widely between individuals and even more so between 
humans and mice(20-22). The functional consequences of these differences and the 
implications for the development of drugs that target this pathway are poorly understood. 
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Quantification of cell protein copy numbers is a critical step in the development of a 
predictive model of platelet activation(23).  Quantitative proteomics, flow cytometry and 
Western blotting have been used to measure human platelet protein copy numbers(24-27).  
Most published reports of platelet protein copy numbers have been in humans and tend to 
focus on a single protein of interest.  No previous study has provided a systematic 
comparison between different quantification methods or between species (human and 
mouse).  Zeiler et al. published the mouse platelet proteome by exploiting quantitative 
proteomics(28) and reported strikingly higher copy numbers of some proteins in mouse 
compared to human platelets, some an order of magnitude higher in mouse than human. 
This was especially surprising since mouse platelets are approximately half the volume of 
human platelets (4.3 fL vs 7.4 fL)(29, 30) implying that the densities of these proteins within 
mouse platelets are higher.  Few studies of mouse protein levels in platelets exist to 
corroborate these surprising findings. One such study quantified mouse Src family kinases 
using western blotting to compare the signal intensity of a platelet lysate with known 
amounts of recombinant protein(31).  The copy number of Src corroborated well with the 
Zeiler et al. proteomic dataset but the copy numbers of Fgr, Fyn and Lyn differed by up to 
240 orders of magnitude.  This may reflect differences in the binding capacity of antibodies 
for the native protein compared to recombinant protein or technical issues associated with 
the analysis of lipid modified proteins by mass spectrometry.   
We sought to independently determine mouse copy numbers of key platelet proteins using 
quantitative flow cytometry as an accessible method to complement mass spectrometry. To 
address the relevance of differences in protein expression we used GPVI as a model 
receptor.  Using a systems pharmacology model of human platelet GPVI signalling, which 
we call the Virtual Platelet(29), the functional implications of discrepancies between levels of 
mouse and human proteins in the GPVI signalling pathway were explored.  The model is a 
dynamic mathematical model that captures the initial events which occur following GPVI 
receptor activation.  We addressed the spatial, temporal and functional questions raised by 
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the mathematical model experimentally using mice expressing kinase dead Syk, western 
blotting for phosphorylated Syk at Y525/526, and super-resolution microscopy.  
Methods 
Flow cytometry to determine surface protein copy number 
Saturating concentrations of fluorescently labelled monoclonal antibodies were applied to 
beads of known antigen binding capacity (Bangs Laboratories) and 106 washed human and 
mouse platelets. Platelets were also incubated with fluorescently labelled IgG to control 
against non-specific antibody binding.  Bead and platelet fluorescence was read using flow 
cytometry (BD Biosciences; FACSVerse, Accuri CSampler Plus).  The geometric mean 
fluorescence was used to construct a standard curve to enable the protein copy number on 
the surface of platelets to be determined.  A linear regression was fitted to the standard 
curve.  Bead saturation is confirmed by a high R2 value close to 1.  All monoclonal and FITC 
conjugated antibodies were from Emfret Analytics (5 µl/106 platelets) except anti-CLEC-2 (10 
µg/ml INU1); anti-CD41 (30 µg/ml MWReg30, BD Biosciences) anti-ADAM10 (10 µl/106 
platelets R&D systems); PE conjugated anti-human GPVI antibody (2.5 µl/106 platelets 
HY101, BD Pharmingen) 
Flow cytometry to determine intracellular protein copy number 
8 x 106 human washed platelets suspended in 1x Hepes Buffered Saline (HBS) were fixed 
with an equal volume of 4% Paraformaldehyde for 10 mins at room temperature.  Platelets 
were washed three times with 1 x HBS with pelleting for 15 mins at 500g.  Platelets were 
permeabilise by incubation with BD Phosflow Perm Buffer III for 30mins on ice.  Following 
three washes with 1x Phosphate Buffered Saline, platelets were incubated with a saturating 
concentration of FITC conjugated anti-human Syk antibody 4D10 or FITC conjugated IgG 
control for 20 minutes at room temperature (20 µg/ml; BD Pharmingen).  The geometric 
mean fluorescence was compared to beads of known antigen binding capacity as described 
above to determine the copy number of human Syk. 
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Virtual Platelet predictions 
The mathematical model used to generate computational predictions (the Virtual Platelet) 
has been described previously(29). The model captures the interactions between key 
proteins downstream of collagen receptor GPVI, and simulations form predictions of how the 
proteins interact, to bind, regulate and activate over time. Experimental data describing the 
copy numbers of the proteins GPVI, Syk, c-Cbl and Tula-2 form model inputs and along with 
estimates of platelet volume, allows numerical solutions of the model (carried out with the 
numerical solver code of R package deSolve(32)) to predict how variation in protein copy 
numbers effects signalling downstream of the GPVI receptor.    
Full details of the interactions captured in the model, its equations and methods of calibration 
and validation are available in Dunster et al., 2015 and an interactive online interface to the 
virtual platelet is provide at https://cardiomaths.shinyapps.io/VirtualPlateletInterspecies and 
the R code available on request. 
Local sensitivity analysis was performed by varying each protein copy number by fifty 
percent above and below their initial value, the time to reach peak Syk activity was 





where Oa and Oi represent the time to reach the peak in Syk activity in respect of the initial 
protein copy numbers. 
Human platelet preparation 
Human platelets were purified from citrated blood from consenting aspirin-free, healthy 
volunteers following procedures approved by the University of Reading Research Ethics 
Committee and prepared as previously described.(29)  
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Mouse platelet preparation 
Procedures were approved by the University of Reading’s Animal Welfare and Ethical 
Review Body.  Blood was obtained from C57/BL6 mice via cardiac puncture into acid citrate 
dextrose (ACD) following CO2 narcosis and platelets prepared (4x108 platelets/ml) as 
previously described.(33)  Platelet aggregation at 2x108 platelets/ml was followed using light 
transmission aggregometry as previously described.(34)   
Syk kinase dead expressing mouse model  
Animal experimentation was performed with ethical approval from the UK Home Office (PPL 
P0E98D513) granted to the University of Birmingham. Syk kinase-dead (Syk KD) mice refer 
to the following novel mouse strain: C57BL/6NTac-Syktm3515(K396R)Arte (Taconic Artemis) which 
expresses a Syk protein with a K396R point mutation in the presence of cre recombinase. 
For this study, mice were crossed with mice carrying the platelet and megakaryocyte specific 
Pf4 promoter driven cre. Experiments were performed by blinding the genotypes prior to the 
experiment and during analysis. 
Syk Y525/526 and LAT Y200 phosphorylation time course.  
Human and mouse washed platelets (4x108 cells/ml) prepared under non-aggregating 
conditions with stirring (1200rpm) for the indicated time points before lysis as described 
previously(26). Anti-phospho Syk (Abcam; ab58575); anti-phospho LAT (Abcam; ab68139); 
anti-Actin antibody (C-11) (Santa Cruz; sc-1615); anti-Syk 4D10 (cell signaling). 
Platelet spreading and staining 
For STORM imaging washed human and mouse platelets were spread on CRP coated 35 
mm #1.5 (0.17mm) glass bottomed dishes (MatTek Corporation, USA) as previously 
described(35).  Fixed and permeabilised platelets were labelled with a pan-Syk antibody 
(Santa Cruz; N-19:sc-1077 used at 1μg/ml) at room temperature for 1 hour followed by anti-
rabbit-Alexa647 (Life Technologies;A-21245 used at 1:300 dilution) secondary labelling and 
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Phalloidin-Alexa488 (1:300 dilution) at room temperature for 1 hour. Samples were washed 
and stored in PBS until imaged. 
STORM Imaging 
Samples were imaged on a Nikon N-STORM system in dSTORM mode which is 
characterized by a Ti-E stand with Perfect Focus, 100 × 1.49 NA TIRF objective lens, Agilent 
Ultra High Power Dual Output Laser bed  (170- mW, 647-nm laser) for the excitation and 
Andor IXON Ultra 897 EMCCD camera for the image acquisition. To allow fluorophore 
blinking, samples were imaged in a PBS based buffer consisting of enzyme solution 
(catalase 1 μg/ml, Tris (2-carboxyelthyl) phosphine hydrochloride 4 mM, glycerol 50%, KCl 
25 mM, pH 7.5 Tris-HCl 20 mM, glucose oxidase 50 µg/ml), glucose solution (glucose 100 
mg/ml, glycerin 10%) and reducing agent solution (100 mM MEA). For single colour 
(Alexa647) the N-STORM emission cube was used and the 405 laser power was then 
increased by 5% every 30 seconds during imaging to reactivate the fluorophore from the 
dark state. 20,000 frames were captured using Nikon NIS Elements v4.5 with an exposure 
time of 20 ms, gain 300 and conversion gain 3, and reconstructed using STORM analysis 
module 3.2, applying the drift correction and the Gaussian rendering. 5 separate fields of 
view (FOV) from 3 independent experiments were imaged for both mouse and human. 
Identified points, which represent individual fluorescent blinking events, were filtered on 
photon count and only those with a count >500 were selected for further cluster analysis.  
Analysis of dSTORM data 
After localizing detections (average precision 10 nm) within NIS elements Density-Based 
Spatial Clustering of Applications with Noise (DBSCAN)(36) was used to group detections 
into clusters. For DBSCAN the radius of the local neighbourhood was set to 25 and the 
minimum number of directly reachable points was set to 10.  Edge points were included in 
clusters.  Cluster area was calculated using the convex hull of all detections within a cluster 
and cluster detection density was defined as the number of detections within a cluster 
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divided by the cluster area.  Analysis was performed on whole fields of view and 
measurements for all clusters within a technical replicate were grouped. This analysis was 
performed using the R package RSMLM (37). To measure cellular area and calculate 
clusters per/µm2 regions of interest (ROIs) were drawn around the cellular boundary using 
the epi image within Nikon NIS Elements.  
Statistical analysis 
Data is presented as the mean ± standard deviation.  Where indicated statistical analysis 
was performed using unpaired two tailed t-test or 2-way ANOVA with Bonferroni post-test.  
All statistical analyses were performed using GraphPad Prism 7. 
Results 
Mouse platelets have a greater density GPVI 
Mouse receptor copy numbers were determined by comparing antibody labelled platelets to 
antibody labelled calibration beads with known antigen binding capacities.  The mean 
fluorescence intensity of platelets stained with a monoclonal antibody to mouse GPVI 
(JAQ1) (Figure 1A) were compared to beads of known antigen binding capacity, also 
labelled with JAQ1 (Figure 1B) which were used to construct a calibration curve (Figure 1C).  
Using this, mouse platelets were determined to have 5,586 ± 1,155 copies of GPVI at the 
cell surface which is similar to proteomic estimates.   
To validate the flow cytometry approach the surface copy number of other membrane 
proteins were determined and compared to the published mouse proteomic database (Table 
1).(28)  Copy number was similar for CLEC-2, integrins α2, αIIb and α6, GPIbα and P-
selectin (activated) platelets, whereas the levels of CD9 and ADAM10 were approximately 
one order of magnitude higher when measured using proteomics.   
The approach was further validated by using the flow cytometry method to determine the 
surface copy number of human GPVI and the intracellular protein copy number of human 
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Syk and compared these to the published human proteomic database (Table 2).(24)  The 
copy number for human Syk was similar, whereas human GPVI was approximately 2 fold 
higher when measured by flow cytometry compared to the proteomic estimation. 
Modelling of mouse GPVI signalling using the Virtual Platelet simulation 
When comparing the published protein copy numbers for proteins involved in the GPVI 
signalling pathway (GPVI, Syk, Cbl and TULA-2) in human and mouse platelets there are 
some striking differences (Figure 1D)(24, 26, 28). One difference of note is the 10 fold 
increase in Syk molecules per mouse platelet compared to human platelets.  Additionally, 
due to the smaller size of mouse platelets compared to human platelets, all molecules 
involved in the initial events downstream of GPVI, including the receptor, are at a greater 
density in mouse platelets than in human (Figure 1E).  
The Virtual Platelet model of human GPVI signalling(29) was used to predict how these large 
differences in mouse platelet protein copy number influence signalling.  The model is able to 
predict the effects of variability in protein copy number on events downstream of the GPVI 
receptor.  We replaced parameters in the Virtual Platelet model with mouse protein copy 
numbers to enable comparison between the dynamics of GPVI signalling between the two 
species (Figure 2A & B).  The model was used to predict the dynamics of Syk tyrosine 
phosphorylation at positions Y525/Y526 (Y519/520 in mouse).  Phosphorylation of 
Y525/Y526 within the activation loop of the kinase domain of human Syk is a recognised Syk 
activation marker(38) and a critical step in GPVI signalling.     
Time-dependent simulations of Syk phosphorylation on the activatory loop (Y525/526) in 
platelets from a hypothetical population of human and mouse donors following ligation of 
GPVI with 10µg/ml CRP display a similar temporal pattern of tyrosine phosphorylation 
(Figure 2A). The virtual human population show a peak in Syk phosphorylation at the 
activatory site occurring in the range of 30-39 seconds following ligand being applied, while 
the virtual mouse population peaked between 18-22 seconds (Figure 2B). 
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Experimental time course of human and mouse Syk activation corroborates the 
outcomes of the modelling 
To corroborate the outcomes of the modelling, experimental time-courses of Syk 
phosphorylation at Y525/526 were determined (Figure 2C and 2D). Due to the high 
sequence similarity between human and mouse Syk, the phospho-specific antibody raised 
against phosphorylated tyrosines Y525/526 recognises the corresponding phosphorylated 
residues Y519/520 in mouse platelets(38).  The time to maximal tyrosine phosphorylation on 
the Syk activatory loop was determined by quantitative Western blotting, which for mouse 
was 31±8 seconds and for human was 34±8 seconds following stimulation with 10μg/ml 
CRP (Figure 2E), similar to the times to peak predicted by the Virtual Platelet model.    
Mouse platelets are refractory to large reductions in the number of Syk molecules  
Modelling was used to determine the sensitivity of Syk phosphorylation at position Y525/526 
in response to variation (±50%) of the key components of the Virtual Platelet model (Figure 
3). The model predicts that the time to peak Syk phosphorylation at the activatory site in 
mouse is, unlike in human platelets, insensitive to a 50% change in Syk copy number.  In 
mouse platelets there is no difference in the predicted timing of Syk activation following 50% 
Syk deficiency predicting that mouse platelets are insensitive to large variations in Syk 
protein copy number (Figure 3).  To test this, using aggregation as a functional endpoint of 
platelet activation, we used a novel mouse model which expresses a kinase dead (K396R) 
form of Syk in mice containing a megakaryocyte lineage specific Cre-deleter, Pf4-Cre(39, 
40).  Platelets express the kinase dead version of Syk and wild type Syk at the same level as 
Syk in control platelets (Supplemental Figure 1).  Heterozygous mice which have both a wild 
type Syk allele and a K396R kinase dead Syk allele were compared to litter mate controls 
(Figure 4A).  No significant difference in total Syk protein levels was observed in the Syk KD 
HT platelets when compared to control platelets (Figure 4B & 4C).  Using the assumption 
that Syk KD HT mice express both wild type and kinase dead versions of Syk in a 1:1 ratio 
we compared the aggregation of platelets from control and Syk KD HT mice in response to 
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10, 3 and 1µg/ml of CRP (Figure 4D and 4E).  No significant difference in percentage 
platelet aggregation at 6mins following agonist addition was observed between control and 
Syk KD HT mouse platelets at any of the concentrations of CRP tested (Figure 4E).  
However, following quantification of the time to peak, a statistically significant delay was 
seen in the aggregation of Syk KD HT following the addition of 3µg/ml CRP (Figure 4F).  No 
significant difference in the time to peak was observed following 10µg/ml CRP.   
Tyrosine phosphorylation on the Syk activatory loop was determined by quantitative Western 
blotting (Figure 4G-I).  As the model predicts, no significant difference was seen in the time 
to maximal tyrosine phosphorylation on the Syk activatory loop between control and Syk KD 
HT mice following stimulation with 10µg/ml CRP.  In addition, no significant difference was 
observed in the phosphorylation of the downstream signalling molecule LAT at position Y200 
(Supplemental Figure 2).  Despite the competition of wild type and kinase dead versions of 
Syk in the heterozygous mice and the dominant negative effect this has on signalling 
outcomes, heterozygous platelets expressing both the wild type and kinase dead version of 
Syk largely have no observable phenotype when stimulated with 10µg/ml CRP and only a 
minor phenotype when stimulated using a reduced concentration of CRP.  These data 
validate the model by demonstrating that mouse platelets are relatively resistant to a 50% 
variation in functional Syk. 
Spatial organisation of Syk in mouse and human platelets 
The spatial distribution of receptors and signalling molecules is an important consideration in 
the regulation of signalling pathways.  We hypothesized that as the initial signalling events 
are similar between mouse and human platelets, both in the Virtual Platelet model and in the 
experimental outcomes, signalling may be regulated by the spatial distribution of signalling 
molecules.  To identify and quantify the spatial distribution of Syk in human and mouse 
platelets the localisation of Syk was imaged by dSTORM super resolution microscopy using 
an Alexa 647 conjugated secondary labelled pan-Syk antibody which cross reacts with both 
human and mouse Syk.  The DBSCAN algorithm was used to determine Syk cluster size, 
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number and detection density within clusters (Figure 5).  DBSCAN identifies clusters by 
grouping points together within a defined local distance provided a minimum number of 
points can be found within that defined distance.  For this analysis, a radius of 25 nm was 
used and the minimum number of points located within the defined radius was 10.    These 
user defined conditions minimised background noise and minimised the merging of discrete 
clusters together (Supplemental Figure 3).  While mouse platelets had significantly more 
detections per cluster, a larger cluster area and an increased number of clusters per unit 
area (Figure 5C, 5D and 5E) there was no significant difference in the Syk detection density 
within clusters between human and mouse (Figure 5F). 
Discussion 
Quantification in biology is of increasing importance, not only to identify potential new drug 
targets, but to also understand the implications of signalling perturbations and variations 
have on functional outcomes by generating models reliable enough for in silico research.  
Here we use flow cytometry to quantify the level of surface receptors and to quantify 
changes in the copy number of membrane receptors at the surface of platelets.     
All platelet surface receptors tested in this study, except the metalloproteinase ADAM10 and 
the tetraspanin CD9, were within two-fold of those determined by quantitative proteomics.  
The flow cytometry approach for these two proteins gave lower surface protein copy 
numbers that were ten times lower that determined by proteomics.  These differences may 
indicate that these proteins have significant intracellular pools or decreased antibody binding 
due to steric hindrance.   Indeed, studies in other cell types demonstrate that, in addition to 
surface expression, ADAM10 is also localised to intracellular pools(41) but it is not known if 
this is the case in platelets.  Tetraspanins are recognised as membrane organisers, 
interacting with other tetraspanins and also other interacting partners such as integrins(42).  
Clustering of CD9 with other tetraspanins and membrane partners in the cell membrane may 
lead to reduced antibody binding due to steric hindrance. 
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While available proteomic datasets provide an estimation of absolute numbers of proteins, 
these data can be combined with flow cytometry to determine the copy number of proteins 
expressed at the surface and used to quantify changes in surface expression.  For example, 
as expected, resting mouse platelets have very little P-selectin molecules at their surface 
(550 ± 290 molecules per platelet).  When activated this increases to 53538 ± 8875 
molecules per platelet.  This value is in the same order of magnitude as the total amount of 
P-selectin identified in the mouse proteomic dataset (35970 ± 2712 molecules per platelet).  
Proteomics provides an indication of total P-selectin protein copy number suggesting that 
following platelet activation the majority of P-selectin is exposed to the surface of platelets. 
42816 ± 637 copies of CLEC-2 were identified on the surface of mouse platelets compared 
to only 2016 ± 239 copies reported on human platelets(43).  The copy number of human 
CLEC-2 determined by flow cytometry supports the Burkhart et al. proteomics data set which 
identified 3700 copies of CLEC-2 per human platelet.  The copy number of mouse CLEC-2 
by flow cytometry strongly supports the mouse proteomic data which identified 41652 ± 7759 
copies of CLEC-2 per mouse platelet(28).  Our data suggest that mouse platelets express 
approximately 20 times more CLEC-2 at their surface than human platelets.  The increase in 
protein copy number may contribute to the recent finding that mouse platelets can adhere to 
and form aggregates on recombinant mouse podoplanin at high shear rates whereas human 
platelets are unable to do so(44, 45).  The difference in CLEC-2 copy number raises the 
suggestion that high levels of Syk in mouse may support other Syk dependent signalling 
events such as those mediated by CLEC-2. 
When comparing the copy numbers of signalling molecules associated with the GPVI 
signalling pathway we were surprised to find that there was a 10-fold increase in Syk 
molecules in mouse platelets compared to human.  Considering how tyrosine kinases play a 
pivotal role in platelet receptor signal transduction we sought to use the Virtual Platelet 
model to explore the effect protein copy number may have on GPVI signalling in mouse 
platelets, particularly in the regulation of Syk.  The model corroborated experimental data 
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demonstrating that phosphorylation of the tyrosines within the Syk activatory loop follow a 
similar time course in mouse and human platelets despite the differences in copy number of 
Syk. 
The Virtual Platelet, a mathematical model of platelet signalling, has allowed the role and 
importance of specific signalling molecules involved in platelet activation to be determined.  
We have used the Virtual Platelet to investigate the functional implications of discrepancies 
between levels of mouse and human proteins in the GPVI signalling pathway.  This has shed 
light on the molecules and processes within platelet cells that regulate GPVI mediated 
signalling.  Models, like the Virtual Platelet, have to the potential to aid the development of 
new anti-platelet therapies, enable correlations between preclinical toxicity screening and 
clinical outcomes, and may facilitate personalised therapy.           
The Virtual Platelet simulation which used the mouse protein levels predicted a slightly larger 
difference in Syk temporal regulation compared with the experimental data.  This may lie in 
the subtle difference in the regulation of Tula-2, a histidine tyrosine phosphatase that 
negatively regulates Syk, between mouse and human(46).  Human Tula-2 has been 
reported to have a dependence on PKC.  Studies used pan-inhibitors of PKC suggests that 
PKC regulation of TULA-2 negatively regulates Syk activation.  Mouse platelets have no 
reported role for PKC in Tula-2 regulation(47).  Mouse platelets may compensate for the loss 
of this second level of regulation by having greater levels of Tula-2 compared to human.  
The counterintuitive increase in human platelet activity in response to increases or 
decreases in Syk copy numbers reflects Syk’s tight control of its own activation and 
inhibition. The copy numbers in human platelets are in balance so that Syk controls its own 
activation.  A mouse model expressing a kinase dead version of Syk was used to investigate 
the impact a loss of functional Syk had on GPVI mediated signalling.  Despite the 
competition of wild type and kinase dead versions of Syk in the heterozygous mice and the 
dominant negative effect this may have on signalling outcomes, heterozygous platelets 
expressing both the wild type and kinase dead version of Syk largely behaved like control 
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platelets in the experimental conditions tested.  The insensitivity of mouse platelets to 
variation in Syk leads to the hypothesis that in mice, concentrations of Syk may be more 
tightly controlled up stream, at the cell membrane.  Indeed, considerable evidence suggests 
that the spatial distribution of signalling assemblies is highly regulated.  Many membrane 
receptors do not function as single signalling units but instead associate in multimolecular 
complexes with the formation of submicron clusters implicated in the initiation, maintenance 
and down regulation of signalling pathways(48-50).   
GPVI has been shown to oligomerise in response to a range of GPVI ligands in human 
platelets(35).   dSTORM allowed fluorophore molecules to be detected and located with high 
spatial precision.  Combined with cluster analysis the relative localisation of Syk molecules in 
human and mouse platelets was determined.  Despite the 10-fold difference in the copy 
number of Syk in mouse platelets there was only a 2.7-fold increase in the number of 
clusters per spread platelet area and a 1.3- and 1.2-fold increase in the cluster area and the 
number of detections per cluster respectively.  Overall there was no significant difference in 
the relative density of Syk within the identified clusters.  This suggests that regulation of 
GPVI signalling may be at the level of receptor and explains why, despite large differences in 
protein copy number, the regulation of GPVI mediated signalling is similar between mouse 
and human. 
In conclusion, we have used a flow cytometry-based method to validate the available mouse 
proteomics data, providing a means to quantify mouse platelet surface protein expression 
and changes induced following platelet activation.  Using a systems pharmacology model of 
human platelet GPVI signalling, the Virtual Platelet, in combination with quantitative western 
blotting and super resolution microscopy we have identified that, despite large differences in 
protein copy number, the regulation of proximal signalling events downstream of GPVI is 
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Table 1 Copy number of major mouse platelet receptors 
Copy number of major mouse platelet receptors determined by flow cytometry values 
presented as the mean ± S.D n>3.  * A comparison has been made with the available mouse 
quantitative proteomics data taken from (28). Proteins highlighted in red are included in the 
Virtual Platelet model. 
 
 
Table 2 Copy number of human GPVI and human Syk 
Copy number of human GPVI and human Syk determined by flow cytometry, values 
presented as the mean ± S.D n≥3.  ** A comparison has been made with the available 
human quantitative proteomics data taken from (24). 
23 
 
Figure 1 Flow cytometry can be used to determine the copy number of mouse 
platelets receptors.  Saturating concentrations of directly dye conjugated monoclonal 
antibodies against mouse GPVI (JAQ1) were used to label platelets (A) and beads of known 
antigen binding capacity (B).  The geometric mean was used to construct a calibration graph 
which can then be used to calculate the number of proteins exposed at the platelet cell 
surface (C).  Comparison between mouse and human platelet copy numbers taken from this 
study, Zeiler et al,(2014) and Mazet et al, (2015) (D). Comparison between mouse and 





Figure 2 Virtual platelet predictions of Syk activity in a hypothetical population of 
mouse and human platelet is supported by the experimental outcomes.   (A) The 
results of 200 simulations of the Virtual platelet are shown. Each line represents a prediction 
of how Syk phosphorylation changes over time in response to protein copy numbers 
randomly selected across their normal range (Human: GPVI, 5000 +/-12%; Syk, 2763 +/-
22%, c-Cbl, 2581 +/-25%. Mouse: GPVI, 5586 +/-12%; Syk, 23286 +/-22%, c-Cbl, 3241 +/-
25%). Simulations representing Syk phosphorylation in a hypothetical mouse platelet 
(n=100) being shown in red or in a human platelet (n=100) in blue.  (B) A summary of model 
predictions for the time to reach maximal peak Syk activity with each simulation denoted 
graphically by a circle.  (C) Representative time-course of Syk Y525/Y526 phosphorylation in 
human and mouse washed platelets following GPVI ligation with 10 µg/ml CRP.  Actin acts 
as a loading control. (D) Quantification of mouse and human Syk Y525/Y526 
phosphorylation time-courses. Mean ± S.D, n=5. (E) Time to maximal Syk Y525/Y526 
phosphorylation.  Line indicates the mean ± S.D. p=0.5796 Statistical analysis was 




Figure 3. Mouse platelets are refractory to large reductions in the number of Syk 
molecules.  Modelling suggests that the sensitivity of Syk phosphorylation to variation in 
protein copy numbers varies between human and mouse platelets.  Time to maximal Syk 
phosphorylation in a hypothetical population of human and mouse platelets is shown, where 
the copy number of each protein was varied by 50% above and below their initial value. A 
positive sensitivity score represents an increase in the time to reach peak activity and a 






Figure 4.  (A) Genotyping strategy confirming the presence of both a Syk WT allele and KD 
version under the control of PF4-Cre in the heterozygous mice (HT) and homozygous mice 
(HO) . (B) Total Syk protein levels were measured by Western blot in control (WT) and Syk 
KD HT (HT) mice using two different anti-Syk antibodies.  (C) Quantification of Syk levels in 
platelets from WT and Syk KD HT mice. Mean ± S.D, n=3. 4D10 p=0.146, N19 p=0.305 
Statistical analysis was performed with unpaired t test (D) Platelet aggregation of washed 
control (WT) and heterozygous (HT) mice induced by 10 and 3 µg/ml CRP (addition of 
agonist indicated by arrowhead).  (E) Quantification of % aggregation at 5 mins of control 
(WT) and Syk KD HT (HT) platelets.  Mean ± S.D, n≥3. Statistical analysis was performed 
with a 2-way ANOVA with Bonferroni post-test (ns; p>0.05)  (F) Quantification of time to 
peak of control (WT) and Syk KD HT (HT) platelets.  Mean ± S.D, n≥3. Statistical analysis 
was performed with a 2-way ANOVA with Bonferroni post-test (ns; p>0.05, *p<0.05) (G) 
Representative time-course of Syk Y525/Y526 phosphorylation in WT and Syk KD HT 
mouse washed platelets following GPVI ligation with 10µg/ml CRP.  Actin acts as a loading 
control. (H) Quantification of control (WT) and Syk KD HT (HT) Syk Y525/Y526 
phosphorylation time-courses. Mean ± S.D, n=3. (I) Time to maximal Syk Y525/Y526 
phosphorylation.  Line indicates the mean ± S.D.  p=0.193 Statistical analysis was 






Figure 5. Spatial distribution of Syk in mouse and human platelets.  Representative plot 
of clusters in a human platelet (A) and a mouse platelet (B) spread on CRP.  Clusters were 
identified using DBSCAN with a radius of 25 nm and a minimum number of points as 10.  
Each cluster is identified by a different colour, the black points are background points which 
do not meet the criteria to be included in a cluster.  Quantification of the number of 
detections per cluster (C), cluster area (D), number of clusters per spread platelet area (E) 
and the detection density within clusters (F) in human and mouse platelets.  Mean ± S.D, 







Supplemental figure 1: Total Syk protein levels were measured by Western blot in control 








Supplemental Figure 2 (A) Representative time-course of LAT Y200 phosphorylation in WT 
and Syk KD HT mouse washed platelets following GPVI ligation with 10µg/ml CRP.  Actin 
acts as a loading control.  (B) Quantification of control (WT) and Syk KD HT (HT) LAT Y200 
phosphorylation time-courses. Mean ± S.D, n=3 (HT), n=2 (WT). (C) Time to maximal LAT 






Supplemental Figure 3. Spatial distribution of Syk in mouse and human platelets.  
Representative plot of clusters in a human platelet (A) and a mouse platelet (B) spread on 
CRP.  Clusters were identified using DBSCAN with the indicated radius (r) and minimum 
number of points (p).  Each cluster is identified by a different colour, the black points are 
background points which do not meet the criteria to be included in a cluster.  Quantification 
of the number of detections per cluster (C), cluster area (D), number of clusters per spread 
platelet area (E) and the detection density within clusters (F) in human and mouse platelets.  
Mean ± S.D, n=3 *p≤0.05 **p≤0.01 Statistical analysis was performed with unpaired t test.   
